Free Radical Theory of Aging: Effect of Age, Sex and Dietary Precursors on Rat-Brain Docosahexanoic Acid*

DENNIS E. EDDY, PhD and DENHAM HARMAN, MD, PhD**

Departments of Medicine and Biochemistry, University of Nebraska College of Medicine, Omaha, Nebraska

ABSTRACT: Increasing the peroxidizability of dietary fat has an adverse effect on the function of the central nervous system (CNS) in the rat. This effect may be influenced by the level of docosahexanoic acid, a highly unsaturated fatty acid, selectively concentrated in the phospholipids of brain membranes. This study was aimed at determining the influence of age, sex, and the nature of a dietary lipid supplement - linolenic acid (18:3w3), docosahexanoic acid (22:6w3), or the same amount of 22:6w3 in the form of menhaden oil triglycerides - on the rate of increase in the percentage of 22:6w3 in the whole-brain fatty acids of rats between the ages of 1 and 12 months. The dietary lipid supplements were reflected in linear increases in the brain 22:6w3 of female rats throughout the study. Between 6 and 12 months of age, the rate of incorporation of dietary 22:6w3 and its precursors into the brain 22:6w3 of male rats dropped. At 12 months it was about half that for females in the case of 22:6w3 and menhaden oil, and about zero for 18:3w3. It is suggested that dietary 22:6w3 and its precursors may modify CNS function by altering membrane function and peroxidizability through changes in the concentration of 22:6w3 in membrane phospholipids.

Rat performance in maze and discrimination learning situations is impaired as the peroxidizability of dietary fat is increased (1). This effect of dietary fat may be produced, at least in part, by enhancing the level of more-or-less random free radical reactions throughout the brain. The enhancement is brought about through increases in the peroxidizability of the dietary fat or through the provision of easily oxidized lipids or their precursors that are concentrated in brain tissues, thereby enhancing the susceptibility of the tissues to free radical reactions.

The major contributor to the possible latter mode of brain dysfunction may be the $\omega 3$ family of fatty acids, the group of polyunsaturated fatty acids whose first double bond, starting from the CH_3 end, is between carbons 3 and 4. Both lino-

lenic acid (carbon number $18:3\omega 3$) and docosahexanoic acid ($22:6\omega 3$) are avidly taken up from the diet (2-4) and reflected in increased brain levels of $22:6\omega 3$. Brain $22:6\omega 3$ is tenaciously retained, resulting in increased levels with increasing age, largely at the expense of $22:5\omega 6$ (2).

Brain $22:6\omega 3$ is concentrated in the phospholipids of neurons, both in the perikaryon and the synaptic area (5–8); the percentages of $22:6\omega 3$ in the acyl chains of the phosphatidylethanolamine, phosphatidylserine plus phosphatidylinositol, and phosphatidylcholine fraction are about 20–30, 10-15 and 1-3 respectively. Retinal rods are also rich in $22:6\omega 3$ (9). Presumably the presence of this highly unsaturated, readily peroxidized, fatty acid in phospholipids has a beneficial effect on membrane permeability to water and organic compounds (10) and on the activities of membrane-bound enzymes (11).

The minimal dietary requirements, if any, for 22:6ω3 or its precursors (mainly 18:3ω3) for satisfactory central nervous system (CNS) function, has not been determined because of difficulties in

^{*} The authors gratefully acknowledge the financial assistance of the late Mrs. Adah Millard, Omaha, Nebraska and of the U.S. Department of Agriculture.

^{**} Address for correspondence: Denham Harman, MD, University of Nebraska Medical Center, 42nd and Dewey Avenue, Omaha, NB 68105.

eliminating 18:3 ω 3 from the diet (3). It is also not known if there is a value or a range of values of brain 22:6 ω 3 associated with optimal brain function.

The purpose of the present study was to determine the influence of age, sex, and the nature of the dietary lipid supplement $-18:3\omega 3$, $22:6\omega 3$ or distilled triglycerides of menhaden oil - on the rate of increase in the percentage of $22:6\omega 3$ in the fatty acids of whole-brain lipid.

METHODS AND RESULTS

The 130 rats used in this study were the seventh generation offspring born in this laboratory of Sprague-Dawley rats obtained (Charles River Breeding Laboratories, Wilmington, MA) at weaning in October 1972. The rats were maintained in an air-conditioned room at 75-78°F at a humidity of 50-60 percent. They were kept, 4 to a cage (stainless steel, $11.5 \times 18.5 \times 6.5$ inches). Cages were changed two or three times per week; the bedding was sterilized shredded corn cobs (Sani-i-Cel, Paxton Processing Co., Paxton, IL). Food and water were provided ad libitum. The 23 dams were given a semisynthetic diet (12) containing 5%w (by weight) of edible grade safflower-olive (oleinate, a mutant of safflower oil in which oleic acid replaces linoleic acid) (Pacific Vegetable Oil Corp., Richmond, CA) and 20 mg of α-tocopherol acetate per 100 grams of finished diet; at 115 days of age, and thereafter, unesterified α - tocopherol was used instead of the acetate. When the rats were 117 days old, 1 male, same age as the females and given prior to mating the same diet, was placed in a cage with 4 females for a period of 7 days and then removed. The offspring (seventh generation) were culled to 8 per litter at 6 days of age. At 23 days of age the 130 rats (67 females and 63 males) were weaned, sexed and caged 4 per cage.

At age 26 days the offspring were divided into three approximately equal groups as shown in Table 1.

The rats of $Group\ I$ were divided into 4 dietary subgroups: 1) control diet; 2) control plus 50 mg of 18:3 ω 3 (Nu Chek Prep, Inc., Elysian, MN); 3) control plus 50 mg of 22:6 ω 3 (90 percent grade, Nu Chek Prep, Inc.); or 4) control plus 377 mg of distilled triglycerides of menhaden oil (kindly supplied by Dr. Neva L. Karrick of the Northwest Fisheries Center, U. S. Dept. of Commerce, Seattle, WA), per 100 grams of finished diet. The fatty acid analyses of the four finished diets are

listed in Table 2. The base diet was prepared every ten to fourteen days and the supplemented diets every six to seven days; the diets were kept in a deep-freeze before use. The rats were fed fresh food daily. Two male and 2 female members of Group I were killed by decapitation on days 0, 15 and 30, and like numbers of rats from each of the supplemented groups were killed after days 10, 20 and 30 of the study.

Group II rats were given the control diet until age 147 days, and Group III rats until age 391 days, before being divided into the 4 dietary subgroups. The decapitation schedule for the supplemented subgroups of Group II and III was the same as for Group I; the numbers of rats for analysis were also the same except that only 1 male was available in the $18:3\omega 3$ subgroup of Group III. In the control subgroup of Group II, 2 male and 2 female rats were killed at the beginning and at the end of the 30-day supplemented period whereas only 1 male and 2 females were available for the control subgroup of Group III; these were killed at the start of the 30-day supplemented period.

After decapitation, whole brains (1.0-1.9) grams, depending upon the age of the rats) were taken immediately, frozen on dry ice, wrapped in aluminum foil and stored in nitrogen-filled vials at -70° C, until the lipid analyses could be carried out. The procedures for brain lipid extraction, conversion of the fatty acid moieties to methyl esters, and analysis of fatty acid composition by gas chromatography have been described previously (2).

The mean \pm the standard error of the mean for the major brain fatty acids for the 4 dietary subgroups for the three supplemented periods are shown in Table 3. The male and female data for Groups I and II, diets supplemented for 30 days starting at age 27 and 147 days respectively, are combined in the table, as they were essentially the same. Individual male and female rat brain data are shown for Group III-diets supplemented for 30 days starting at age 391 days, along with the averages of the combined data. The data of Table 3 for total brain $22:5\omega 6$ and $22:6\omega 3$, are presented graphically in Figure 1, A and B. The changes in the percentage of 22:4ω6, 22:5ω6 and $22.6\omega 3$ in total brain lipids of rats on the base diet are shown in Figure 2 as a function of age from 26 to 391 days.

The differences between the percentages of a given fatty acid at the end of the 30-day supplemented dietary fat period and at the start for each of the given dietary subgroups, for each of

TABLE 1

Effect of Age, Sex, and Dietary Fat on Fatty Acid Composition of Total-Brain Lipids in Sprague-Dawley Rats. (Supplemental Lipid Feeding Periods and Autopsy Schedule)

		Die	tary Fat S	Suppleme	nt*
Group	Age (days)	None	18:3ω3	22:6ω3	Men- haden Oil
			Autopsy	Schedule)
1-48 rats	26 36	2M†,2F‡	2M,2F	2M,2F	2M,2F
	41 46 56	2M,2F 2M,2F	2M,2F 2M,2F	2M,2F 2M,2F	2M,2F 2M,2F
2-44 rats	147 157 167	2M,2F	2M,2F 2M,2F	2M,2F 2M,2F	2M,2F 2M,2F
	177	2M,2F	2M,2F	2M,2F	2M,2F
3-38 rats	391 401 411 421	1M,2F	1M,2F 2M,2F 2M,2F	2M,2F 2M,2F 2M,2F	2M,2F 2M,2F 2M,2F

^{*} At 26, 147 and 391 days of age, groups of rats that had been receiving base diet were subdivided into 4 dietary groups by adding either nothing (control), 50 mg of $18:3\omega 3$, 50 mg of $22:6\omega 3$, or 377 mg of distilled triglycerides of menhaden oil to the diet.

the three supplemented periods, are shown in Table 4. Changes in $22:6\omega 3$ are shown in Figure 3.

DISCUSSION

The percentage of $22:6\omega 3$ in the total-brain lipid of rats receiving the base diet rose steadily, almost linearly for females and somewhat less so for males, throughout the course of this study — from age 26 days to age 391 days. The increases in brain $22:6\omega 3$ with age are due to the small amount (about 0.1 percent) of $18:3\omega 3$ present in the safflower-olive (oleinate) in the base diet. The increases in brain $22:6\omega 3$ were roughly paralleled by the decreases in $22:5\omega 6$.

Increases in dietary $18:3\omega 3$, $22:6\omega 3$ or distilled triglycerides of menhaden oil were reflected in virtually linear increases in the percentage of brain $22:6\omega 3$ during the three age periods studied, viz, 26-56, 147-177 and 391-421 days. The increases for the age period 26-56 days were nearly the same when the diet was supplemented with either 50 mg of $22:6\omega 3$ per 100 grams of diet or 377 mg of distilled triglycerides of menhaden oil (containing 50 mg of $22:6\omega 3$ in ester form) -8.1 per cent and 10.6 per cent respectively. The increase produced by adding 50 mg of $18:3\omega 3$ to

100 grams of the base diet was about half, i.e., 3.9 per cent. The increase in brain $22.6\omega3$ resulting from administration of the three lipid supplements during the second age period, 147-177 days, was roughly half that observed for the first age period. During the third age period, 391-421 days, the percentage increase of $22.6\omega3$ in brain total lipid was the same as for the second age period for all three lipid supplements for females, but about half for males receiving $22.6\omega3$ or menhaden oil and practically zero for males receiving $18.3\omega3$.

Previous work (2) indicated that the level of 22:6ω3 in total brain lipid would increase little after 6 months of age; therefore the present experiment was programmed for one year. This impression was in error. Instead, at 12 months of age, the female rat continues to convert dietary 18:3ω3 and 22:6ω3 (the latter either as the free acid or in glyceride form) into brain 22:6ω3 at the same steady linear rate as observed at 147–177 days of age. This ability is significantly impaired in males, particularly for 18:3ω3.

The maximum percentage of $22:6\omega 3$ in the total brain lipid of male and female rats that can be achieved by dietary manipulation, is not known. In this study the highest brain $22:6\omega 3$ level, 13.1

TABLE 2
Fatty Acid Composition of the Diets

a 1		Di	iet	
Carbon Num- ber	Base*	18:3ω3**	22:6ω3†	Menhaden Oil‡
10	0.10	0.14	0.21	
12	_	_	_	0.22
14	0.20	0.23	0.23	1.16
15§	`0.01	0.02	0.02	0.08
16	5.79	5.43	5.36	8.20
16:1ω7	_	_	_	0.57
17:1§	_	_		0.13
18	0.67	0.44	0.75	0.67
18:1ω9	71.43	70.78	69.38	61.66
$18:2\omega 6$	19.74	19.29	19.70	20.61
20	_	_	0.12	0.23
$18:3\omega 3$	0.10	2.47	0.13	0.08
20:1ω7	0.18	0.10	0.17	0.86
20:2§	1.56	1.04	0.24	0.44
$20:4\omega 6$	_	_	_	0.13
$20:5\omega 3$	_	_	_	2.31
22:1	_	_		0.43
$22:6\omega 3$	_	_	3.65	1.68

^{*} Semisynthetic diet containing, as sole source of lipid, 5%w of oleinate and 20 mg of α -tocopherol per 100 grams of finished diet.

[†] Male.

[‡] Female.

^{** 50} mg of $18:3\omega 3$ added per 100 grams of base diet.

^{† 50} mg of 22:6 ω 3 (90% grade) added per 100 grams of base diet.

 $[\]ddagger$ 377 mg of distilled triglycerides of menhaden oil (equivalent to 50 mg of 22:6 ω 3) added per 100 grams of base diet.

[§] Tentative identification.

TABLE 3

Effect of Age, Sex, and Dietary Fat on Fatty Acid Composition of Total-Brain Lipids in Sprague-Dawley Rats

			56	+1	+1	+I	12.2 ± 0.1	+I	+1	+I			99	+	20.7 ± 0.2	+I	ΗI	+1	+1	+I	ø			177	+1	+I	ŧΙ	ΗI	3.4 ± 0.2	+I	+1
days of age	CD + 18:3ω3	Age, Days	46	+1	+1	+1	12.7 ± 0.1	÷Ι	+I	+1	CD + Menhaden Oil	Age, Days	46	+1	20.2 ± 0.1	ŧΙ	+1	+I	+1	10.8 ± 0.4	m 147 to 177 days of ag	CD + 18:3ω5	Age, Days	167	1 +1	+1	+1	+1	3.5 ± 0.1	+1	+1
nhaden oil, from 27 to 46			36	+1	+1	+1	13.4 ± 0.3	ŧΙ	ŧΙ	+I		-	36	18.9 ± 0.2		+1	+I	ΗI	+1	6.7 ± 0.3	rides of menhaden oil, fro			157	+1	+I	ΗI	+I	3.4 ± 0.1	+I	+1
A. Group I: Control diet supplemented with 18:3w3, 22:6w3 or menhaden oil, from 27 to 46 days of age			26	+1	+1	+I	12.2 ± 0.7	ŧΙ	ŧΙ	+1			26	17.9 ± 0.1	20.2 ± 0.1	+1	+I	+1	ΗI	10.1 ± 0.3	temented with 18:3w3, 22:6w3 or distilled triglycerides of menhaden oil, from 147 to 177 days of age			177	+1	ŧΙ		+I	3.6 ± 0.1	ŧΙ	+1
ontrol diet supplemented	Control Diet (CD)	Age, Days	41	+1	+I	+1	13.2 ± 0.1	ŧ١	+1	+I	CD + 22:6 3	Age, Days	46	+1	20.6 ± 0.2	ΗI	ŧΙ	+1	+I	7.6 ± 0.3	pplemented with 18:3w3,	Control Diet (CD)	Age, Days	167							
A. Group I: Co			26	+1	+I	20.0 ± 0.6	ΗI	4.5 ± 0.1	ΗI	ΗI			36	19.3 ± 0.1	+1	20.3 ± 0.1	ΗI	4.1 ± 0.2	13.1 ± 0.1	4.8 ± 0.2	B. Group II: Control diet suppl			147	+1	+1	+1	+I	+I	+I	+1
		Corpor	Number	16	18	18:1ω9	$20.4\omega 6$	22:4w6	22:5w6	$22.6\omega_3$			Number	16	18	$18:1\omega 9$	20:4w6	22:4w6	22:5w6	22:6w3	B		, and and a	Number	16	18	18:1∞9	20:4∞6	$22.4\omega 6$	$22.5\omega 6$	22:6w3

The control of the supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3 or distilled triglycerides of menhaden oil, frontrol diet supplemented with 18:3u3, 22:6u3, 22:6u3, 22:6u3, 22:2u3, 23:2u3, 23	C. Group III: Control diet supplem C. Group III: Control diet supplem C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 39.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 29.2 28.8) + 22:6ω3			
17.3 ± 0.2 20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 Correspond III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 11.3 11.1	157 17.3 ± 0.2 20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 3.0 3.2 7.0 8.1 6.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 7.1 8.3			CD + Menhaden Oil	
C. Group III: 7.2	C. Group III: 20.1 Tr.3 ± 0.2 20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 39 Female Transle 17.8 17.2 19.8 19.4 27.9 11.3 11.7 3.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 39.4 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.2 28.8 11.3 11.1 39.7 20.1 29.7 28.8 11.3 11.1 29.7 28.8	ge, Days		Age, Days	
17.3 ± 0.2 20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 11.3 11.1	17.3 ± 0.2 20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 29.2 28.8 7.9 9.7 8.0 9.1 8.3 9.6 8.2 8.2 8.3 9.6 8.2 8.3 9.6 8.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8.6 9.6 9.6 8		157	167	177
20.1 ± 0.9 26.6 ± 0.7 1.18 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 Temale Temale 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.1 8.3	20.1 ± 0.9 26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 29.2 28.8 7.9 9.6 9.7 41 41 41 41 41 41 41 41 41 41 41 41 41	± 0.1 17.1 ±	+1	l +ı	+1
26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 Corrected diet supplem Corrected diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 7.1 8.3	26.6 ± 0.7 11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 11.3 11.1 3.0 0.0 41 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 29.2 28.8 7.9 9.0	± 0.3 18.8 ±	ŧΙ	+1	+1
11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 Correspond III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 11.3 11.1 3.2 2.8 7.1 8.3	11.8 ± 0.2 3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.5 11.3 11.1 39.2 29.2 28.8 11.3 11.1 29.2 28.8 11.3 29.2 28.8 11.3 29.2 28.8 11.3 29.2 28.8	± 0.2 27.7 ±	+1	+1	+1
3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.1 8.3	3.3 ± 0.2 11.1 ± 0.6 4.5 ± 0.3 C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 32.2 28.8 11.3 11.1 3.0 29.2 28.8 11.3 11.1 3.0 29.2 28.8 11.3 11.1 3.0 29.2 28.8	± 0.2 11.7 \pm	+i	+1	+1
C. Group III: Control diet supplem Pemale 17.3 17.2 19.8 19.4 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.1 8.3	C. Group III: ± 0.6 4.5 ± 0.3 Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.0 6.0 8.1	+ 0.2	+1	+1	+I
C. Group III: Control diet supplem Cor Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.1 8.3	C. Group III: Control diet supplem Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.0 8.3	+ 0.3	+1	+1	6.8 ± 0.4
C. Group III: Control diet supplem Cor Female 17.3 17.2 19.8 19.4 27.8 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.1 8.3	C. Group III: Control diet supplem Pemale 17.3 17.2 19.8 19.4 27.9 11.3 11.7 3.0 3.2 9.6 8.2 7.0 8.1 Female Female 16.5 16.1 19.4 20.1 29.2 28.8 11.3 11.1 3.2 2.8 7.0 8.1	± 0.4 8.1 ±	+1	+1	+1
Control Diet (CD) S91 Days of Age	Semale Male Avg. ± 8.E 17.3 17.2 16.8 17.1 ± 0.1 19.8 19.4 19.9 19.7 ± 0.1 19.8 19.4 28.5 28.1 ± 0.2 11.3 11.7 11.9 11.6 ± 0.2 11.3 11.7 11.9 11.6 ± 0.2 11.3 11.7 11.9 11.6 ± 0.2 11.4 12.1 16.1 16.1 11.5 16.1 16.1 16.2 11.5 16.1 16.1 16.2 11.6 16.1 16.1 16.2 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.1 11.8 11.4 10.1 11.3 11.1 11.1 11.4 11.1 11.5 11.5 ± 0.2 11.6 11.7 11.7 11.8 11.5 ± 0.2 11.6 12.5 11.6	ted with 18:3a3, 22:6a3 or distilled triglyceride	es of menhaden oil, fror	n 391 to 421 days of a	ag
Female Male Avg. ± s.g.M. Female 17.3 17.2 16.8 16.8 17.1 ± 0.2 16.6 16.5 19.8 19.4 19.9 19.7 ± 0.1 19.6 20.4 27.8 27.9 28.5 28.1 ± 0.2 28.2 27.9 11.3 11.7 11.9 11.6 ± 0.2 11.6 10.8 3.0 3.2 2.8 2.9 2 3.0 ± 0.4 7.4 9.5 20.2 28.8 29.6 29.3 29.2 ± 0.2 17.2 15.4 19.4 20.1 19.4 19.1 11.7 11.8 11.5 ± 0.2 10.9 11.3 29.2 28.8 29.6 29.3 29.2 ± 0.2 29.3 2.9 3.2 29.3 2.8 2.8 2.8 2.8 2.8 2.8 3.5 3.3 ± 0.2 2.9 3.2 29.3 2.8 3.5 3.3 ± 0.2 2.9 3.2 29.4 2.8 3.5 8.5 8.5 8.5 8.5 8.5 8.5	Female Male Avg. ± s.g. 17.3 17.2 16.8 17.1 ± 0.5 19.4 19.9 19.7 ± 0.5 19.8 27.9 28.5 28.1 ± 0.5 11.3 11.7 11.9 11.6 ± 0.5 3.0 3.2 9.2 9.2 9.0 ± 0.5 5.0 8.1 6.1 7.0 ± 0.1 16.5 16.1 16.7 16.5 ± 0.5 16.5 16.1 16.7 16.5 ± 0.5 16.5 16.1 16.7 16.5 ± 0.5 11.3 11.1 11.7 11.8 11.5 ± 0.5 11.3 11.1 11.7 11.8 11.5 ± 0.5 11.3 11.1 11.7 11.8 11.5 ± 0.5 11.3 11.1 11.7 11.8 11.5 ± 0.5 11.3 11.1 11.7 11.8 11.5 ± 0.5 11.5 11.5 11.5 ± 0.5 11.5 11.5 11.5 ± 0.5 11.5 11.5 11.5 ± 0.5 11.5 11.5 11.5 ± 0.5 11.5 11	ol Diet (CD)		CD + 18:3ω3	
Female Male Avg. ± s.e.m. Female 17.3 17.2 16.8 10.2 16.6 16.5 19.8 19.4 19.9 19.7 ± 0.1 19.6 20.4 27.8 27.9 28.5 28.1 ± 0.2 27.9 11.3 11.7 11.9 11.6 10.8 3.2 ± 0.1 3.0 3.2 3.5 3.2 ± 0.1 3.2 3.0 9.6 8.2 9.2 9.2 9.0 ± 0.4 7.4 9.5 7.0 8.1 6.1 10.3 1.2 16.7 16.7 16.5 ± 0.2 11.5 10.7 16.7 16.7 16.5 ± 0.2 11.5 10.1 11.7 11.8 11.5 ± 0.2 29.2 28.8 29.2 28.8 29.2 28.8 29.2 ± 0.2 29.3 28.8 29.8 29.8 29.2 ± 0.2 29.3 28.8 29.8 29.8 29.8 ± 0.2 29.3 28.8 3.5 3.5 3.5 3.3 3.3 2.3 29.3 28.8 29.8 29.8 29.8 29.8 29.8 29.8 29.8	Female Male Avg. ± 8.E 17.3 17.2 16.8 17.1 ± 0. 19.8 19.4 19.1 19.9 19.7 ± 0. 27.8 27.9 28.5 28.1 ± 0. 11.7 11.9 11.6 ± 0. 27.0 8.1 6.1 7.0 ± 0.0 Female Male Avg. ± 8.E 16.5 16.1 16.7 16.7 16.5 ± 0. 11.3 11.1 11.7 11.8 11.5 ± 0. 29.2 28.8 29.6 29.3 29.2 ± 0. 29.2 28.8 29.6 29.3 29.2 ± 0. 29.2 28.8 3.5 3.5 ± 0. 29.2 28.8 29.8 29.8 29.2 ± 0. 29.2 28.8 29.8 29.8 29.8 29.2 ± 0. 20.3 28.8 29.8 29.8 29.8 29.2 ± 0. 20.4 18.3 8.5 8.5 8.1 ± 0. 20.5 20.8 29.8 29.8 29.8 29.8 ± 0. 20.7 20.8 29.8 29.8 29.8 29.8 ± 0. 20.8 29.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 29.8 ± 0. 20.9 2 28.8 29.8 29.8 29.8 29.8 29.8 29.8	Days of Age		401 Days of Age	
17.317.216.817.1 ± 0.216.616.519.819.419.919.7 ± 0.119.620.427.827.928.528.1 ± 0.228.227.911.311.711.911.6 ± 0.211.610.83.03.23.53.2 ± 0.13.23.09.68.29.29.0 ± 0.47.49.57.08.16.17.0 ± 0.68.67.8CD + 18:3ω3411 Days of AgeFemaleMaleAvg. ± s.g.M.Female16.516.716.716.5 ± 0.217.215.419.420.119.419.119.5 ± 0.228.728.829.228.829.529.229.2 ± 0.229.728.728.811.311.111.711.811.5 ± 0.22.93.27.18.38.58.58.1 ± 0.37.86.6	17.3 17.2 16.8 17.1 ± 0.2 19.8 19.4 19.9 19.7 ± 0.2 27.8 27.9 28.5 28.1 ± 0.2 3.0 3.2 3.5 3.2 ± 0.2 9.0 8.1 6.1 7.0 ± 0.4 11.3 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 11.4 12.1 13.5 13.5 13.5 11.5 12.5 13.5 13.5 11.5 12.5 13.5 11.5 12.5 13.5 11.5 13.5 13.5 11.5 13.5 13.5 11.5	Avg. ±	Female	Male	Avg. ± s.e.m.
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	19.8 19.4 19.9 19.7 ± 0. 27.8 27.9 28.5 28.1 ± 0. 11.3 11.7 11.9 11.6 ± 0. 3.0 3.2 3.5 3.2 ± 0. 3.6 8.2 9.2 9.0 ± 0. 7.0 8.1 6.1 7.0 ± 0.0 Female Male Avg. ± s.E 16.5 16.1 16.7 16.7 16.5 ± 0. 19.4 20.1 19.4 19.1 19.5 ± 0. 29.2 28.8 29.6 29.3 29.2 ± 0. 11.3 11.1 11.7 11.8 11.5 ± 0. 29.6 29.3 29.2 ± 0. 29.7 28.8 3.5 3.5 3.3 ± 0. 29.7 29.8 29.8 29.8 29.2 ± 0. 29.8 28.8 29.8 29.8 29.2 ± 0. 29.9 28.8 29.8 29.8 29.2 ± 0. 29.9 28.8 29.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 ± 0. 29.9 28.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 ± 0. 29.9 29.8 29.8 29.8 29.8 29.8 29.8 29.8	17.1 ±		17.4	+1
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	27.8 27.9 28.5 28.1 ± 0. 11.3 11.7 11.9 11.6 ± 0. 3.0 3.2 3.2 ± 0. 3.5 3.2 ± 0. 3.2 ± 0. 9.2 9.0 ± 0. 7.0 ± 0.1 411 Days of Age 16.5 16.1 16.7 16.5 ± 0. 19.4 20.1 19.4 19.1 19.5 ± 0. 29.2 28.8 29.6 29.3 29.2 ± 0. 11.3 11.1 11.7 11.8 11.5 ± 0. 29.2 28.8 3.5 3.5 3.3 ± 0. 20.5 2.6 2.7 7.0 ± 0.	19.7 ±		19.1	+1
11.3 11.7 11.9 11.6 \pm 0.2 11.6 10.8 3.2 \pm 0.1 3.2 \pm 0.1 3.2 3.0 3.2 \pm 0.1 3.2 \pm 0.1 3.2 3.0 3.2 \pm 0.1 4 7.4 9.5 7.0 8.1 6.1 7.0 \pm 0.6 8.6 7.8 CD + 18:3 \pm 3.2 10.2 28.8 29.2 28.8 29.6 29.3 29.2 \pm 0.2 28.8 29.8 29.8 29.3 29.2 \pm 0.2 28.8 29.8 29.8 29.8 29.3 29.2 \pm 0.2 28.8 29.8 29.8 29.8 29.8 29.8 29.8 29	11.3 11.7 11.9 11.6 ± 0.5 3.0 3.2 3.5 3.2 ± 0.5 9.6 8.2 9.2 9.0 ± 0.0 7.0 8.1 6.1 7.0 ± 0.0 CD + 18:3ω3 411 Days of Age Female Male Avg. ± s.E 16.5 16.1 16.7 16.7 16.5 ± 0.2 19.4 20.1 19.4 19.1 19.5 ± 0.2 29.2 28.8 29.6 29.3 29.2 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 3.2 2.8 3.5 3.5 3.3 ± 0.2 7.0 ± 0.2 7.0 ± 0.3	28.1 ±		28.8	28.3 ± 0.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	3.0 3.2 3.5 3.2 ± 0. 3.6 8.2 9.2 9.2 9.0 ± 0. 7.0 8.1 6.1 7.0 ± 0.0 CD + 18:3ω3 411 Days of Age 16.5 16.1 16.7 16.7 16.5 ± 0. 19.4 20.1 19.4 19.1 19.5 ± 0. 11.3 11.1 11.7 11.8 11.5 ± 0. 11.3 12.2 8.8 29.6 29.3 29.2 ± 0. 11.3 11.1 11.7 11.8 11.5 ± 0. 12.4 20.1 8.3 8.5 8.5 8.1 ± 0. 13.5 ± 0.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5 5.5	11.6 ±		11.8	ΗI
9.6 8.2 9.2 9.0 ± 0.4 7.4 9.5 7.0 ± 0.6 8.1 7.0 ± 0.6 8.6 7.8 7.8 7.0 ± 0.6 8.1 8.6 7.8 7.0 ± 0.6 8.1 8.5 8.2 8.2 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 28.8 29.2 29.2	9.6 8.2 9.2 9.0 ± 0.7.0 ± 0.0 ± 0.7.0 ± 0.0 ± 0.7.0 ± 0.0 ±	3.2 +		3.7	+1
7.0 8.1 6.1 7.0 \pm 0.6 8.6 7.8 CD + 18:3 ω 3 CD + 18:3 ω 3 411 Days of Age Female Male Avg. \pm s.e.M. Female 16.5 16.1 16.7 16.7 16.5 \pm 0.2 17.2 15.4 19.4 19.1 19.4 19.1 19.5 \pm 0.2 28.8 29.2 28.8 29.6 29.3 29.2 \pm 0.2 28.8 29.6 29.3 29.2 \pm 0.2 28.8 3.3 \pm 0.2 2.8 3.5 8.5 8.5 8.5 8.1 \pm 0.3 7.8 6.6	7.0 8.1 6.1 7.0 ± 0.0 CD + 18:3ω3 411 Days of Age Female Male Avg. ± s.E 16.5 16.1 16.7 16.7 16.5 ± 0.3 19.4 20.1 19.4 19.1 19.5 ± 0.3 29.2 28.8 29.6 29.3 29.2 ± 0.3 11.3 11.1 11.7 11.8 11.5 ± 0.3 7.1 8.3 8.5 8.5 8.1 ± 0.3 7.2 2.8 8.5 8.5 8.1 ± 0.3 7.3 1.5 1.5 1.5 ± 0.3 7.4 1.8 1.8 1.1 1.1 1.1 1.1 1.1 1.1 1.1 1.1	± 0.6		9.5	÷Ι
Female Male Avg. ± s.E.M. Female 16.5 16.1 16.7 16.7 16.7 16.5 ± 0.2 29.2 28.8 29.6 29.3 29.2 ± 0.2 11.3 11.1 11.7 11.8 11.5 ± 0.2 7.1 8.3 8.5 8.5 8.5 8.5 8.1 ± 0.3	Female Male Avg. ± s.g. 16.5 16.1 16.7 16.7 16.5 ± 0.1 19.4 20.1 19.4 19.1 19.5 ± 0.2 29.2 28.8 29.6 29.3 29.2 ± 0.1 11.3 11.1 11.7 11.8 11.5 ± 0.2 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	7.0 ±		6.4	+I
Female Male Avg. ± s.E.M. Female 16.5 16.1 16.7 16.7 16.7 16.5 ± 0.2 17.2 15.4 19.4 20.1 19.4 19.1 19.5 ± 0.2 28.7 28.8 29.2 28.8 29.6 29.3 29.2 ± 0.2 28.7 28.8 11.3 11.1 11.7 11.8 11.5 ± 0.2 10.9 11.3 3.2 2.8 3.5 3.5 8.5 8.5 8.5 8.5 8.1 ± 0.3 7.8 6.6	Female Male Avg. ± s.E. 16.5 16.1 16.7 16.7 16.7 16.5 ± 0.3 19.4 20.1 19.4 19.1 19.5 ± 0.2 29.2 28.8 29.6 29.3 29.2 ± 0.3 11.3 11.1 11.7 11.8 11.5 ± 0.3 3.2 2.8 3.5 3.5 3.5 3.3 ± 0.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0	+ 18:3ω3		CD + 18:3ω3	
Female Male Avg. \pm s.E.M. Female Male Male Avg. \pm s.E.M. Female Male Male Male Avg. \pm s.E.M. Female Male M	Female Male Avg. ± s.g. 16.5 16.1 16.7 16.5 ± 0.3 19.4 20.1 19.4 19.1 16.5 ± 0.3 29.2 28.8 29.6 29.3 29.2 ± 0.3 11.3 11.1 11.7 11.8 11.5 ± 0.3 3.2 2.8 3.5 3.3 ± 0.3 7.0 8.5 8.5 8.1 ± 0.3	Days of Age		421 Days of Age	
16.5 16.1 16.7 16.7 16.5 ± 0.2 17.2 15.4 19.6 19.4 20.1 19.4 19.1 19.5 ± 0.2 19.4 19.5 29.2 28.8 29.6 29.3 29.2 ± 0.2 28.7 28.8 29.5 11.3 11.1 11.7 11.8 11.5 ± 0.2 10.9 11.3 11.9 3.2 2.8 3.5 3.5 3.5 3.2 2.9 3.2 3.4 7.1 8.3 8.5 8.5 8.1 ± 0.3 7.8 6.6 9.6	16.5 16.1 16.7 16.5 16.5 19.4 20.1 19.4 19.1 19.5 ± 29.2 28.8 29.6 29.3 29.2 ± 11.3 11.1 11.7 11.8 11.5 ± 3.2 2.8 3.5 3.5 3.3 ± 7.1 8.3 8.5 8.5 8.1 9.0 9.1 7.0 7.0	Avg. ± S.E	Female	Male	Ave. ± s.E.M.
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	19.4 20.1 19.4 19.1 19.5 ± 29.2 28.8 29.6 29.3 29.2 ± 11.3 11.1 11.7 11.8 11.5 ± 3.2 2.8 3.5 3.5 3.3 ± 7.1 8.3 8.5 8.5 8.1 ± 9.0 9.1 9.5 9.5 9.1 ±	16.7 16.5 ±			+1
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	29.2 28.8 29.6 29.3 29.2 ± 11.3 11.1 11.7 11.8 11.5 ± 11.5	19.1 19.5 ±			ŧΙ
11.3 11.1 11.7 11.8 11.5 ± 0.2 10.9 11.3 11.9 3.2 2.8 3.5 3.5 3.3 ± 0.2 2.9 3.2 3.4 7.1 8.3 8.5 8.5 8.1 ± 0.3 7.8 6.6 9.6	11.3 11.1 11.7 11.8 11.5 ± 3.2 2.8 3.5 3.5 3.3 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.5 8.5 8.5 8.5 8.1 ± 7.1 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3 8.3	29.3 29.2 ±			ŧΙ
$3.2 2.8 \qquad 3.5 3.5 3.3 \pm 0.2 \qquad 2.9 3.2 \qquad 3.4$ $7.1 8.3 \qquad 8.5 8.5 \qquad 8.1 \pm 0.3 \qquad 7.8 6.6 \qquad 9.6$	3.2 2.8 3.5 3.5 3.3± 7.1 8.3 8.5 8.5 8.1 ± 0.0 0.1 6.6 6.9 7.0 ±	11.8 11.5 ±			ŧΙ
$7.1 8.3 \qquad 8.5 8.5 \qquad 8.1 \pm 0.3 \qquad 7.8 6.6 \qquad 9.6$	7.1 8.3 8.5 8.5 8.1 = 8.1 = 8.1 =	3.5 3.3 ±			+1
	+ 0.4 5.7 LD 0.5	8.5 8.1 +			8.2 ± 0.7

TABLE 3-Continued

	C. Grou,	p III: Co	introl die	t supplen	rented with 18:30	υ3, 22:6	w3 or distilled CD + 22:6w3	istilled tr 22:6ω3	iglyceria	C. Group III: Control diet supplemented with 18:3ω3, 22:6ω3 or distilled triglycerides of menhaden oil, from 391 to 421 days of age CD + 22:6ω3	, from 39	1 to 421	days of e	əSt	
Carbon			401 Day	401 Days of Age				411 Day	411 Days of Age				421 Day	421 Days of Age	
Number	Fei	Female	M	Male	Avg. ± s.E.M.	Female	nale	W	Male	Avg. ± s.e.m.	Female	ale	Mg	Male	Avg. ± S.E.M.
16	16.6	16.4	17.1	16.7	16.7 ± 0.2	16.7	17.0	16.8	16.9	16.8 ± 0.1	17.1	15.8	16.9	16.7	16.6 ± 0.3
18	19.0	19.4	19.4	19.9	19.4 ± 0.2	19.6	19.1	20.0	20.5	19.7 ± 0.3	19.4	19.5	19.8	19.6	19.6 ± 0.1
$18:1\omega_9$	28.6	28.9	28.8	29.3	28.9 ± 0.1	28.2	28.3	28.8	30.0	28.8 ± 0.4	28.1	28.6	29.4	29.2	28.8 ± 0.3
$20.4\omega 6$	11.4	11.3	11.9	11.7	11.6 ± 0.1	11.5	11.6	11.3	11.0	11.4 ± 0.1	11.1	11.2	11.5	11.2	11.3 ± 0.1
$22.4\omega 6$	3.3	3.0	3.6	3.5	3.4 ± 0.1	3.2	3.3	3.1	3.2	3.2 ± 0.1		ლ ლ	3.0	3.4	+1
$22.5\omega 6$	8.9	œ ??	8.7	9.1	8.8 ± 0.2	8.9	7.5	8.0	9.7	7.5 ± 0.3	5.7	9.9	7.7	2.0	6.7 ± 0.4
22:6w3	8.5	9.3	6.5	5.8	7.5 ± 0.8	10.3	9.3	7.5	7.7	ŧΙ	11.7	11.2	8.0	8.5	+1
						CD	+ Men	CD + Menhaden Oil	_						
Carbon	į		401 Day	401 Days of Age				411 Day	411 Days of Age				421 Day	421 Days of Age	
Number	Fen	Female	M	Male	Avg. ± s.E.M.	Fen	Female	M	Male	Avg. ± s.E.M.	Fen	Female	Ψ̈́	Male	Avg. ± s.E.M.
16	16.1	16.9	17.0	16.5	16.6 ± 0.2	16.6	16.7	16.6	16.6	16.6 ± 0.0	16.1	17.2	17.1	16.8	16.8 ± 0.3
18	19.4	20.0	18.4	20.0	19.4 ± 0.4	18.9	18.3	19.9	20.2	ŧΙ	19.2	19.9	18.7	19.0	19.2 ± 0.3
18:1ω9	30.7	28.3	29.2	8.8	29.3 ± 0.5	28.4	28.8	29.1	30.0	+1	28.2	26.3	29.7	28.2	28.1 ± 0.7
$20.4\omega 6$	10.8	11.3	12.2	11.9	11.6 ± 0.3	11.5	11.6	11.7	11.0	ŧΙ	11.3	12.4	11.4	11.4	11.6 ± 0.3
$22.4\omega 6$	3.0	3.1	3.4	3.3 5.3	3.2 ± 0.1	3.1	3.2	3.7	3.2	ΨI	3.3 3.3	3.2	3.0	3.1	3.1 ± 0.1
$22.5\omega 6$	9.7	8.5	8.6	8.8	8.4 ± 0.3	9.9	6.4	7.3	6.9	6.8 ± 0.2	5.1	7.3	7.9	6.9	6.8 ± 0.6
22:6ω3	9.5	8.6	6.5	6.7	7.7 ± 0.7	10.7	11.4	7.6	9.7	+1	13.1	11.5	8.0	9.7	+I




Fig. 1. Effect of age, sex and dietary fat on: A. The percentage of 22:5w6 in the fatty acids of whole-brain lipid. B. The percentage of 22:6w3 in the fatty acids of whole-brain lipid. (Sprague-Dawley rats.)

AGE, DAYS

167

177 391

401

157

per cent of total fatty acids, was observed for a female rat given menhaden oil supplement for 30 days starting at age 391 days; the corresponding value for males from the same menhaden oil group was 9.7. It is also not known if neuronal populations differ in fatty acid composition and ability to concentrate $22:6\omega 3$, nor if the composition of the components of the synaptic areas mirror corresponding elements of the perikaryon.

41 46

56 147

36

The fact that $22:6\omega 3$ is selectively concentrated

in brain phospholipids suggests that it has a beneficial effect on membrane function, probably on permeability and membrane-bound enzymes. Hence the findings of the present study imply that variations in CNS function between individuals may be partially a reflection of the variables influencing brain 22:6 ω 3 levels, viz, age, sex and dietary precursors. This suggestion is supported by the recent observation (13) that the performance of rats in a discrimination learning situa-

411

421

tion was correlated positively with the level of $22:6\omega 3$ in brain phosphatidylethanolamine and phophatidylserine-phosphatidylinositol. Brain $22:6\omega 3$ levels were altered by feeding semisynthetic diets containing safflower oil, corn oil or soybean oil as the sole source of lipid.

It would be anticipated that as the percentage of $22:6\omega 3$ in total brain lipid increased, lipid peroxidation would increase (even though dietary vitamin E was more than sufficient to prevent overt vitamin E deficiency) and at some point might result in clinically significant behavioral

changes. These changes would not necessarily be accompanied by decrements in other body tissues because of the lesser tendency of $22:6\omega 3$ to concentrate in them. Thus, enhanced lipid peroxidation in the synaptic areas, which are rich in polyunsaturated fatty acids, might contribute to deleterious alterations in behavior in a manner similar to that caused by β -hydroxydopamine (14) or by the anesthetic, halothane (15, 16). Support for this possibility comes from studies of neuritic plaques (senile plaques). The plaques, present in the cortex and basal ganglia of normal




Fig. 2. Effect of age on the percentage of 22:4w6, 22:5w6, and 22:6w3 in the fatty acids of whole-brain lipid of rats receiving the base diet.




Fig. 3. Effect of age, sex and dietary fat on the percentage increase in 22:6w3 in the fatty acids of whole-brain lipid during each of the three 30-day supplemented feeding periods.

Effect of Age and Sex on Changes in Whole-Brain Fatty Acid Composition Produced by Supplementing the Diet for 30 Days with Either 18:3, 22:6 or Menhaden Oil (Sprague-Dawley)

							d d	ercent Ch	ange in F	Percent Change in Fatty Acid Composition	Compositio	ä				
Age (days)		Diet		16:0	18:0	0	18:109	69	Carbon 20:4	Carbon Number 20:4ω6	22:4ω6	900	22:5w6	90	$22:6\omega_3$	ಣ್ಣ
27-56	Base	+ 18:3*		-2.35 -2.39	0.80	0 &	2.61	22	12.2	-2.87 -2.78	0 0	-0.24 -0.62	-0.60	60	0.19	G. ~
	: :	+ 22:6 + Menh.	(-2.71 -2.77	1.2	e 0	22.03	11 9 9	က် ကုံ 	.13	_1 _0_	.19 .94	9 6	20 18	8.0¢ 10.6¢	 C
147-177	Base "	+ 18:3 + 22:6 + Menh.	1111	-1.21 -0.76 -1.08 -1.05	0.71 -0.03 0.01 0.65	3 1 3 2	1.77 1.80 1.51 0.52	2557	0 0 1 1	-0.68 -0.61 -1.05	0000	-0.11 -0.33 -0.27 -0.54	-2.50 -3.21 -4.55 -6.55	50 21 55 55	0.52 2.25 4.15 4.85	Ø1 10 10 10
391-421	Base**	* + 18:3 + 22:6 + Menh.	M† 0.13 0.04	F‡ -0.98 -1.04	M - -0.70 -0.17	F -0.12 -0.14	M - 0.75 0.78 0.41	F - 0.87 -0.47	M - -0.16 -0.54 -0.50	F - 0.41 - 0.39	M - -0.30 -0.27 -0.41	F - 0.11 0.20 0.11	M - -0.01 -1.89	F - 1.73 - 2.73 - 2.69	M -0.06 2.07 2.77	F 2.24 3.81 4.78
Ē	i i												ı			

* The base diet was supplemented with either 50 mg of linolenic acid (18:3\omega6), docosahexanoic acid (22:6\omega3) or 377 mg of distilled triglycerides of ** Data available only for rats aged 391 days.

† Male.

‡ Female.

old people (17), are increased in senile persons (18). The first changes seen in the development of the plaques are alterations in the mitochondria of the axon terminals (19). These mitochondrial changes may be due to peroxidation, for the mitochondria have both a high degree of lipid unsaturation and a high rate of oxygen utilization. The foregoing may be the basis for the observation that rats receiving a semisynthetic diet containing distilled triglycerides of menhaden oil performed more poorly in a Hebb-Williams maze than had been anticipated from mortality data (1).

The present study also suggests that variability in the period of senility prior to death in humans may be due, at least in part, to the differences in brain $22.6\omega 3$ attributable to sex and variation in the amount and kind of brain $22.6\omega 3$ dietary precursors consumed throughout life. Further, it would be anticipated that variable degrees of dysfunction might occur throughout the CNS with time because of local differences in factors, other than lipid, which influence lipid peroxidation. Among these factors are the rate of oxygen utilization, the concentration of α -tocopherol, and the concentration of peroxidation catalysts such as copper and iron (20).

REFERENCES

- Harman D, Hendricks S, Eddy DE et al: Free radical theory of aging: effect of dietary fat on central nervous system function. J Am Geriatrics Soc 24: 301, 1976.
- Eddy DE and Harman D: Rat brain fatty acid composition: effect of dietary fat and age, J Gerontol 30: 647, 1975.
- Tinoco J, Williams MA, Hincenbergs I et al: Evidence for nonessentiality of linolenic acid in the diet of the rat, J Nutr 101: 937, 1971.
- Walker RL: Maternal diet and brain fatty acids in young rats, Lipids 2: 497, 1967.
- 5. Tamai Y, Matsukawa S and Satake M: Lipid composi-

- tion of nerve cell perikarya, Brain Res 26: 149, 1971.
- Cotman C, Blank ML, Moehl A et al: Lipid composition of synaptic plasma membranes isolated from rat brain by zonal centrifugation, Biochem 8: 4606, 1969.
- Sun GY and Sun AY: Phospholipids and acyl groups of synaptosomal and myelin membranes isolated from the cerebral cortex of squirrel monkey (Saimiri seiureus), Biochem Biophys Acta 280: 306, 1972.
- Breckenridge WC, Gombos G and Morgan IG: The docosahexaenoic acid of the phospholipids of synaptic membranes, vesicles and mitochondria, Brain Res 33: 581, 1971
- Anderson RE and Sperling L: Lipids of ocular tissues.
 VII. Positional distribution of the fatty acids in the phospholipids of bovine retinal rod outer segments, Arch Biochem Biophys 144: 673, 1971.
- Chapman D: The role of fatty acids in myelin and other important brain structures, in Lipids, Malnutrition and the Developing Brain, ed. by K Elliott and J Knight. New York, Associated Scientific Publishers, 1972, pp 31-57.
- Mavis RD and Vagelos PR: The effect of phospholipid fatty acid composition in membranous enzymes in Escherichia coli, J Biol Chem 247: 652, 1972.
- Harman D: Free radical theory of aging: effect of the amount and degree of unsaturation of dietary fat on mortality rate, J Gerontol 26: 451, 1971.
- Lamptey MS and Walker BL: A possible essential role for dietary linolenic acid in the development of the young rat, J Nutr 106: 86, 1976.
- Heikkila RE and Cohen G: β-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate, Science 181: 456, 1973.
- Quimby KL, Aschkenase LJ and Bowman RE: Enduring learning deficits and cerebral synaptic malformation from exposure to 10 parts of halothane per million, Science 185: 615, 1974.
- Van Dyke RA and Wood CL: In vitro studies on irreversible binding of halothane metabolite to microsomes, Drug Metab & Dispos 3: 51, 1975.
- Dayan AD: Quantitative histological studies on the aged human brain. I. Senile plaques and neurofibrillary tangles in "normal" patients, Acta Neuropathol (Berlin) 16: 85, 1970.
- Tomlinson, BE, Blessed G and Roth M: Observations on the brains of demented old people, J Neurol Sci 11: 205, 1970.
- Wisniewski HM and Terry RD: Morphology of the aging brain, human and animal, Progr Brain Res 40: 167, 1973.
- Barden H: The histochemical relationships and the nature of neuromelanin, Aging 1: 79, 1975.